Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs

Isoniazid and rifapentine treatment effectively reduces persistent M. tuberculosis infection in macaque lungs

A once-weekly oral dose of isoniazid and rifapentine for 3 months (3HP) is recommended by the CDC for treatment of latent tuberculosis infection (LTBI). The aim of this study is to assess 3HP-mediated clearance of M. tuberculosis bacteria in macaques with asymptomatic LTBI. Twelve Indian-origin rhes...

Full description

Bibliographic Details
Main Authors:	Riti Sharan, Shashank R. Ganatra, Dhiraj K. Singh, Journey Cole, Taylor W. Foreman, Rajesh Thippeshappa, Charles A. Peloquin, Vinay Shivanna, Olga Gonzalez, Cheryl L. Day, Neel R. Gandhi, Edward J. Dick Jr., Shannan Hall-Ursone, Smriti Mehra, Larry S. Schlesinger, Jyothi Rengarajan, Deepak Kaushal
Format:	Article
Language:	English
Published:	American Society for Clinical Investigation 2022-09-01
Series:	The Journal of Clinical Investigation
Subjects:	Infectious disease
Online Access:	https://doi.org/10.1172/JCI161564

Similar Items

Antiretroviral therapy timing impacts latent tuberculosis infection reactivation in a Mycobacterium tuberculosis/SIV coinfection model
by: Riti Sharan, et al.
Published: (2022-02-01)

Inhibition of indoleamine dioxygenase leads to better control of tuberculosis adjunctive to chemotherapy
by: Bindu Singh, et al.
Published: (2023-01-01)

Characterizing Early T Cell Responses in Nonhuman Primate Model of Tuberculosis
by: Riti Sharan, et al.
Published: (2021-08-01)

Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection
by: Weeraya Phaisal, et al.
Published: (2022-09-01)

Short-course isoniazid plus rifapentine therapy for latent tuberculosis in Brazil
by: Julio Croda
Published: (2015-10-01)

Pharmacoprophylactic equivalence of rifapentine compared with isoniazid: an appraisal for HIV-infected population
by: Beuy Joob, et al.
Published: (2021-01-01)

Cost effectiveness of three months of rifapentine and isoniazid for latent tuberculosis in Syrian refugees
by: Ghassan Ilaiwy, et al.
Published: (2021-08-01)

Cost-effectiveness of 3-months isoniazid and rifapentine compared to 9-months isoniazid for latent tuberculosis infection: a systematic review
by: Wendy A. Lai, et al.
Published: (2022-12-01)

Rifapentine and isoniazid for prevention of tuberculosis in people with diabetes (PROTID): protocol for a randomised controlled trial
by: Nyanda Elias Ntinginya, et al.
Published: (2022-06-01)

Rifapentine
by: Paula Mckenzie, et al.
Published: (2014-07-01)

Three months of rifapentine and isoniazid for latent tuberculosis infection in hemodialysis patients: High rates of adverse events
by: Shang-Yi Lin, et al.
Published: (2019-02-01)

High rate of completion for weekly rifapentine plus isoniazid treatment in Chinese children with latent tuberculosis infection-A single center study.
by: Heng Yang, et al.
Published: (2021-01-01)

Treatment of latent Mycobacterium tuberculosis infection with 12 once weekly directly-observed doses of isoniazid and rifapentine among persons experiencing homelessness.
by: Nwabunie Nwana, et al.
Published: (2019-01-01)

Uptake and Completion of Tuberculosis Preventive Treatment Using 12-Dose, Weekly Isoniazid–Rifapentine Regimen in Bangladesh: A Community-Based Implementation Study
by: Md. Toufiq Rahman, et al.
Published: (2023-12-01)

Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model.
by: Ian M Rosenthal, et al.
Published: (2007-12-01)

Efficacy of Short-course Weekly Isoniazid and Rifapentine Regimen as Tuberculosis Preventive Treatment among Population at Risk of Developing Disease: A Systematic Review and Meta-analysis
by: Ilangovan Ilavarasan, et al.
Published: (2024-02-01)

Treating latent tuberculosis infection (LTBI) with isoniazid and rifapentine (3HP) in an inner-city population with psychosocial barriers to treatment adherence: A qualitative descriptive study
by: Amber Heyd, et al.
Published: (2021-01-01)

Treating latent tuberculosis infection (LTBI) with isoniazid and rifapentine (3HP) in an inner-city population with psychosocial barriers to treatment adherence: A qualitative descriptive study.
by: Amber Heyd, et al.
Published: (2021-01-01)

Efficacy and completion rates of rifapentine and isoniazid (3HP) compared to other treatment regimens for latent tuberculosis infection: a systematic review with network meta-analyses
by: Christopher Pease, et al.
Published: (2017-04-01)

Immune Responses in Lung Granulomas during Mtb/HIV Co-Infection: Implications for Pathogenesis and Therapy
by: Deepak Kaushal, et al.
Published: (2023-09-01)

System-wide identification of myeloid markers of TB disease and HIV-induced reactivation in the macaque model of Mtb infection and Mtb/SIV co-infection
by: Maya Gough, et al.
Published: (2022-10-01)

Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trial.
by: Fred C Semitala, et al.
Published: (2021-12-01)

THE ANTI-TUBERCULOSIS ANTIBIOTIC OF RIFAPENTINE: PERSPECTIVES OF CLINICAL USE
by: A. G. Samoylova, et al.
Published: (2019-01-01)

Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial.
by: Fred C Semitala, et al.
Published: (2024-02-01)

THE SAFETY AND EFFICACY OF RIFAPENTINE USED TO TREAT DRUG-SUSCEPTIBLE PULMONARY TUBERCULOSIS
by: N. V. Litvinova, et al.
Published: (2014-04-01)

Experience of using rifapentine in continuation phase of treatment of adult tuberculosis cases
by: T. I. Morozova, et al.
Published: (2019-07-01)

Development and in vitro characterization of drug delivery system of rifapentine for osteoarticular tuberculosis
by: Wu J, et al.
Published: (2015-03-01)

Peripheral Blood Markers Correlate with the Progression of Active Tuberculosis Relative to Latent Control of <i>Mycobacterium tuberculosis</i> Infection in Macaques
by: Maya Gough, et al.
Published: (2022-05-01)

The Use of Rifapentine for Preventive Chemotherapy in Children from Risk Groups of Developing Tuberculosis
by: O. D. Baronova, et al.
Published: (2022-09-01)

Evaluation of drug-drug interaction between rilpivirine and rifapentine using PBPK modelling
by: Sandra Grañana-Castillo, et al.
Published: (2022-12-01)

Optimization of Rifapentine-Loaded Lipid Nanoparticles Using a Quality-by-Design Strategy
by: Joana Magalhães, et al.
Published: (2020-01-01)

Abnormal Dexamethasone Suppression Tests in a Rifapentine-Treated Patient With Primary Aldosteronism
by: Hongman Wang, et al.
Published: (2020-09-01)

Rifapentine is an entry and replication inhibitor against yellow fever virus both in vitro and in vivo
by: Xijing Qian, et al.
Published: (2022-12-01)

Development of Rifapentine-Loaded PLGA-Based Nanoparticles: In vitro Characterisation and in vivo Study in Mice
by: Liang Q, et al.
Published: (2020-10-01)

Gene expression profiles of wild-type and isoniazid-resistant strains of Mycobacterium smegmatis
by: Jyothi Padiadpu, et al.
Published: (2015-09-01)

In Vitro Activity of Rifampin, Rifabutin, and Rifapentine against Enterococci and Streptococci from Periprosthetic Joint Infection
by: Mariana Albano, et al.
Published: (2021-09-01)

Transcriptional Response of Mycobacterium tuberculosis to Cigarette Smoke Condensate
by: Danicke Willemse, et al.
Published: (2021-10-01)

Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis
by: Valéria G. F. Pinheiro, et al.

A mechanism study on the synergistic effects of rifapentine and fluconazole against fluconazole-resistant Candida albicans in vitro
by: Yulian Wang, et al.
Published: (2024-03-01)

Rifapentine-linezolid-loaded PLGA microspheres for interventional therapy of cavitary pulmonary tuberculosis: preparation and in vitro characterization
by: Huang J, et al.
Published: (2017-03-01)